HCW Biologics Inc. Pre-Tax Income
HCW Biologics Inc. (HCWB) reported Pre-Tax Income of -$5.22 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Income Statement
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest · last filed 2026-08-14
- HCW Biologics Inc. income (loss) from continuing operations before income taxes, noncontrolling interest for the quarter ending 2026-06-30 was -$5.22M.
- HCW Biologics Inc. income (loss) from continuing operations before income taxes, noncontrolling interest for the quarter ending 2026-03-31 was $3.80M.
- HCW Biologics Inc. income (loss) from continuing operations before income taxes, noncontrolling interest for the quarter ending 2025-06-30 was -$1.93M.
- HCW Biologics Inc. income (loss) from continuing operations before income taxes, noncontrolling interest for the quarter ending 2025-03-31 was -$2.20M.
- HCW Biologics Inc. income (loss) from continuing operations before income taxes, noncontrolling interest for fiscal 2025 was -$7.96M.
- HCW Biologics Inc. income (loss) from continuing operations before income taxes, noncontrolling interest for fiscal 2024 was -$30.02M.
- HCW Biologics Inc. income (loss) from continuing operations before income taxes, noncontrolling interest for fiscal 2023 was -$24.99M.
- HCW Biologics Inc. income (loss) from continuing operations before income taxes, noncontrolling interest for fiscal 2022 was -$14.90M.
| Period end | Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 3 month | Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 6 month | Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 12 month |
|---|---|---|---|
| 2026-06-30 | -$5.22M 10-Q · filed 2026-08-14 | -$1.42M 10-Q · filed 2026-08-14 | |
| 2026-03-31 | $3.80M 10-Q/A · filed 2026-08-14 | ||
| 2025-12-31 | -$7.96M 10-K · filed 2026-03-31 | ||
| 2025-06-30 | -$1.93M 10-Q · filed 2026-08-14 | -$4.12M 10-Q · filed 2026-08-14 | |
| 2025-03-31 | -$2.20M 10-Q/A · filed 2026-08-14 | ||
| 2024-12-31 | -$30.02M 10-K · filed 2026-03-31 | ||
| 2023-12-31 | -$24.99M 10-K · filed 2025-03-28 | ||
| 2022-12-31 | -$14.90M 10-K/A · filed 2024-05-15 | ||
| 2021-12-31 | -$12.86M 10-K · filed 2023-03-28 | ||
| 2020-12-31 | -$5.80M 10-K · filed 2022-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| REVELATION BIOSCIENCES, INC. (REVB) | United States | $0.004B | |
| Onconetix, Inc. (ONCO) | United States | $0.004B | |
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |